| Literature DB >> 21876824 |
Abdelfatah A Elasfar1, Hatem F Elsokkary.
Abstract
Background. Despite the high technical expertise in percutaneous mitral commissurotomy (PMC), mitral regurgitation (MR) remains a major procedure-related complication. The aim of this work is to find out the most sensitive and applicable predictors of development of significant mitral regurgitation (SMR) following percutaneous mitral commissurotomy using Inoue balloon technique. Methods. We studied prospectively the preprocedural (clinical, echocardiography, and hemodynamic) and procedural predictors of significant mitral regurgitation (identified as increase of ≥2/4 grades of pre-PMC MR by color Doppler flow mapping) following valvuloplasty using Inoue balloon in 108 consecutive patients with severe mitral stenosis. Multiple stepwise logistic regression analysis was performed for variables found positive on univariate analysis to determine the most important predictor(s) of developing SMR. Results. The incidence of SMR following PMC using Inoue technique was 18.5% (10 patients). MV scoring systems were the only variables that showed significant differences between both groups (Group A without SMR and Group B with SMR). However, no clinical, other echocardiographic measurements, hemodynamic or procedural variables could predict the development of SMR. Using multiple regression analysis, the best predictive factor for the risk of SMR after Inoue BMV was the total MR-echo score with a cutoff point of 7 and a predictive percentage of 97.7%. Conclusions. The total MR-echo score is the only independent predictor of SMR following PMC using Inoue technique with a cutoff point of 7.Entities:
Year: 2011 PMID: 21876824 PMCID: PMC3157670 DOI: 10.4061/2011/703515
Source DB: PubMed Journal: Cardiol Res Pract ISSN: 2090-0597 Impact factor: 1.866
Baseline Characteristics.
| Variable | Group A ( | Group B ( |
|
|---|---|---|---|
| Clinical Characteristics: | |||
| (i) Age (Years) | 31 ± 9 | 32 ± 10 | 0.86 |
| (ii) Male/Females | 22/66 | 6/14 | 0.58 |
| (iii) Height | 159 ± 7 | 157 ± 5 | 0.81 |
| (iv) BSA | 1.6 ± 0.2 | 1.6 ± 0.3 | 0.92 |
| (v) Prior PMC | 13.6% | 15.8% | 0.95 |
| (vi) NYHA Class | 2.6 ± 0.7 | 2.7 ± 0.8 | 0.94 |
| (vii) AF | 27.2% | 31.6% | 0.59 |
|
| |||
| Pre-PMC Echo-Doppler data (except MV Scoring): | |||
| (i) MVA (cm2) | 0.9 ± 0.2 | 0.8 ± 0.2 | 0.37 |
| (ii) MG | 14 ± 3 | 13 ± 2 | 0.71 |
| (iii) SPAP | 44 ± 20 | 41 ± 21 | 0.67 |
| (iv) LA dimension | 4.8 ± 1.0 | 4.9 ± 0.7 | 0.47 |
BSA: body surface area; NYHA: New York Heart Association classification; AF: atrial fibrillation. *Significant at <0.05
Hemodynamic and procedural data.
| Variable | Group A ( | Group B ( |
|
|---|---|---|---|
| Pre-Procedural Hemodynamic Data: | |||
| (i) LAP | 25.8 ± 6.6 | 30.3 ± 5.7 | 0.16 |
| (ii) LVEDP | 6.3 ± 2.0 | 5.9 ± 2.4 | 0.57 |
| (iii) Transmitral PG | 20.5 ± 6.8 | 24.3 ± 8.1 | 0.14 |
|
| |||
| Procedural (Technical) Data: | |||
| (i) Balloon Size | 26.5 ± 0.9 | 26.0 ± 1.1 | 0.27 |
| (ii) No. of Inflations | 2.0 ± 0.9 | 2.1 ± 1.1 | 0.28 |
*Significant at <0.05
MV Scoring Systems.
| Variable | Group A ( | Group B ( |
|
|---|---|---|---|
| (A) Wilkins Score: | |||
| (i) Mobility | 2.4 ± 0.5 | 2.7 ± 0.9 | 0.38 |
| (ii) Thickening | 2.2 ± 0.4 | 2.3 ± 0.5 | 0.59 |
| (iii) Subvalvular | 1.5 ± 0.5 | 1.7 ± 0.7 | 0.48 |
| (iv) Calcification | 0.9 ± 0.7 | 2.0 ± 0.7 | 0.006* |
| (v) Total Score | 7.1 ± 1.7 | 8.9 ± 2.1 | 0.028* |
|
| |||
| (B) MR-echo Score: | |||
| (i) Anterior Leaflet | 1.8 ± 0.7 | 2.5 ± 0.5 | 0.024* |
| (ii) Posterior Leaflet | 1.6 ± 0.6 | 2.5 ± 0.7 | 0.010* |
| (iii) Commissures | 1.2 ± 0.5 | 2.5 ± 1.1 | 0.002* |
| (iv) Subvalvular | 1.5 ± 0.5 | 1.7 ± 0.7 | 0.49 |
| (v) Total Score | 6.2 ± 1.0 | 9.3 ± 1.4 | 0.001* |
|
| |||
| (C) Commissural Score: | |||
| (i) Total Score | 0.7 ± 0.6 | 2.0 ± 0.9 | 0.003* |
*Significant at <0.05